Occurrence of hyperoxia during iNO treatment for persistent pulmonary hypertension of the newborn: a cohort study.
Justine de JagerFleur BrouwerJeroen ReijmanRoel L F van der PalenSylke J SteggerdaRemco VisserArjan B Te PasJanneke DekkerPublished in: European journal of pediatrics (2024)
High concentrations of oxygen are often needed to optimize oxygenation in infants with persistent pulmonary hypertension (PPHN), but this can also increase the risk of hyperoxemia. We determined the occurrence of hyperoxemia in infants treated for PPHN. Medical records of infants ≥ 34 + 0 weeks gestational age (GA) who received inhaled nitric oxide (iNO) were retrospectively reviewed for oxygenation parameters during iNO therapy. Oxygen was manually titrated to target arterial oxygen tension (PaO 2 ) 10-13 kPa and peripheral oxygen saturation (SpO 2 ) 92-98%. The main study outcomes were the incidence and duration of hyperoxemia and hypoxemia and the fraction of inspired oxygen (FiO 2 ). A total of 181 infants were included. The median FiO 2 was 0.43 (IQR 0.34-0.56) and the maximum FiO 2 was 1.0 in 156/181 (86%) infants, resulting in at least one PaO 2 > 13 kPa in 149/181 (82%) infants, of which 46/149 (31%) infants had minimal one PaO 2 > 30 kPa. SpO 2 was > 98% in 179/181 (99%) infants for 17.7% (8.2-35.6%) of the iNO time. PaO 2 < 10 kPa occurred in 160/181 (88%) infants, of which 81/160 (51%) infants had minimal one PaO 2 < 6.7 kPa. SpO 2 was < 92% in 169/181 (93%) infants for 1.6% (0.5-4.3%) of the iNO time. Conclusion: While treatment of PPHN is focused on preventing and reversing hypoxemia, hyperoxemia occurs inadvertently in most patients. What is Known: • High concentrations of oxygen are often needed to prevent hypoxemia-induced deterioration of PPHN, but this can also increase the risk of hyperoxemia. • Infants with persistent pulmonary hypertension may be particularly vulnerable to the toxic effects of oxygen, and hyperoxemia could further induce pulmonary vasoconstriction, potentially worsening the condition. What is New: • Hyperoxemia occurs in the majority of infants with PPHN during treatment with iNO. • Infants with PPHN spent a considerably longer period with saturations above the target range compared to saturations below the target range.
Keyphrases
- pulmonary hypertension
- nitric oxide
- gestational age
- type diabetes
- pulmonary artery
- stem cells
- risk assessment
- oxidative stress
- adipose tissue
- pulmonary arterial hypertension
- pet ct
- cell therapy
- preterm birth
- risk factors
- skeletal muscle
- blood flow
- patient reported outcomes
- drug induced
- nitric oxide synthase
- high glucose